Revvity VEGF (mouse) LANCE Ultra TR-FRET Detection Kit; 500 assay points

The LANCE Ultra Mouse VEGF-A Detection Kit is designed for detection and quantitation of human CXCL1/GRO-α in cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

The 500 point kit contains enough reagents to run 500 wells in 384-well format, using a 20 µL reaction volume (15 µL of sample). The 10,000 point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 µL reaction volume (15 µL of sample).

• No-wash steps, no separation steps
• TR-FRET technology
• Sensitive detection
• High reproducibility
• Faster time-to-results
• Easy automation
• 96-well, 384-well, and 1536-well formats

LANCE and LANCE (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight^™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.

Mouse Vascular Endothelial Growth Factor (VEGF-A or VEGF) is a homodimeric 46 kDa heparin-binding glycoprotein specific for endothelial cells. Mouse VEGF is the product of a single gene containing eight exons, which produces three splice variants containing 120, 164, and 188 amino acid residues. The various isoforms have different heparin binding properties as well as solubility characteristics reflecting the different functional properties of the VEGF forms. VEGF is believed to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. Elevated levels of VEGF have been observed in synovial fluids of rheumatoid arthritis patients and sera of cancer patients.